Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label...

Area of Science:

• Neuroscience
• Clinical Neurology
• Immunology

Background:

• Cognitive impairment, particularly affecting frontal and parietal lobes, is common in multiple sclerosis (MS) patients.
• This cognitive decline often does not correlate with neurological disability or disease duration.
• Neuropsychological diagnostic tools are essential for identifying frontal/prefrontal cognitive impairment in MS.

Purpose of the Study:

• To assess the clinical impact of interferon beta-1b (IFNbeta-1b) on cognitive function and event-related potentials in MS patients over one year.
• To compare the effects of IFNbeta-1b on cognitive function with changes in the Expanded Disability Status Scale (EDSS).

Main Methods:

• A prospective, open-label study involving 16 relapsing-remitting MS patients.
• Assessed cognitive function using the Wisconsin Card Sorting Test (frontal lobe) and event-related potential P300 (parietal lobe) before and after one year of IFNbeta-1b treatment.
• Correlated changes in P300 and Wisconsin test scores with baseline values using paired t-tests.

Main Results:

• IFNbeta-1b treatment led to significant improvements in P300 amplitude and latency (P=0.026 and P=0.002, respectively).
• Significant enhancements were observed in Wisconsin Card Sorting Test scores, indicating improved frontal lobe function (P=0.001 for raw score, P=0.0025 for standard score).
• A slight, non-significant improvement in EDSS scores was noted after one year of treatment.

Conclusions:

• IFNbeta-1b demonstrates a positive therapeutic effect on cognitive dysfunction in MS patients.
• The observed cognitive benefits of IFNbeta-1b are independent of its effects on the EDSS score or the overall disease course.
• Addressing cognitive decline in MS is crucial as it negatively impacts patients' quality of life across daily living domains.